{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:27:38Z","timestamp":1784003258129,"version":"3.55.0"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Schizophrenia is a serious mental disorder with high disability rates, and antipsychotics, especially second\u2010generation ones like aripiprazole, are the cornerstone of treatment. As a novel formulation, oral soluble films (OSF) offer an alternative to tablets or capsules, improving patient compliance. This study aimed to assess the bioequivalence, pharmacokinetic (PK) properties, and safety of aripiprazole OSF and aripiprazole orally disintegrating tablets (ODT) in healthy Chinese participants. A\u00a0single\u2010dose, randomized, open\u2010label, and crossover study was conducted. Participants received 10\u2009mg of test aripiprazole OSF (Qilu Pharmaceutical) and reference aripiprazole ODT (Otsuka Pharmaceutical) under fasting and fed states. The fasting trial comprised a three\u2010sequence, three\u2010period design, while the fed trial comprised a two\u2010sequence, two\u2010period design. In the fasting trial, after single oral dosing of aripiprazole OSF (with water), aripiprazole OSF (without water), and aripiprazole ODT, C<jats:sub>max<\/jats:sub> were 55\u2009\u00b1\u200910\u2009ng\/mL, 54\u2009\u00b1\u200910\u2009ng\/mL, and 48\u2009\u00b1\u200913\u2009ng\/mL, respectively; the AUC<jats:sub>0\u201072h<\/jats:sub> were 1857\u2009\u00b1\u2009377\u2009h\u00b7ng\/mL, 1823\u2009\u00b1\u2009350\u2009h\u00b7ng\/mL, and 1745\u2009\u00b1\u2009405\u2009h\u00b7ng\/mL, respectively. In the fed trial, after single oral dosing of aripiprazole OSF and ODT with water, the C<jats:sub>max<\/jats:sub> were 43\u2009\u00b1\u20099\u2009ng\/mL and 43\u2009\u00b1\u200910\u2009ng\/mL, respectively; AUC<jats:sub>0\u201072h<\/jats:sub> were 2024\u2009\u00b1\u2009387\u2009h\u00b7ng\/mL and 1994\u2009\u00b1\u2009426\u2009h\u00b7ng\/mL, respectively. In terms of bioequivalence evaluation, the 90% confidence intervals of the geometric mean ratio of the main PK parameters of aripiprazole OSF and ODT in the fasting and fed states were all within the acceptable equivalence range (80%\u2013125%). Both formulations were well\u2010tolerated. In conclusion, aripiprazole OSF and ODT reached bioequivalence, and aripiprazole OSF demonstrates significant potential for application in the treatment of psychiatric disorders.<\/jats:p>","DOI":"10.1111\/cts.70142","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:40:02Z","timestamp":1739364002000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bioequivalence of Aripiprazole Oral Soluble Films and Orally Disintegrating Tablets in Healthy Participants: A Crossover Study"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2862-7334","authenticated-orcid":false,"given":"Ruoming","family":"Li","sequence":"first","affiliation":[{"name":"Peking University HuiLongGuan Clinical Medical School Beijing HuiLongGuan Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Yang","sequence":"additional","affiliation":[{"name":"Peking University HuiLongGuan Clinical Medical School Beijing HuiLongGuan Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guigang","family":"Yang","sequence":"additional","affiliation":[{"name":"Peking University HuiLongGuan Clinical Medical School Beijing HuiLongGuan Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Gu","sequence":"additional","affiliation":[{"name":"Qilu Pharmaceutical Co. Ltd.  Jinan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuokai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Qilu Pharmaceutical Co. Ltd.  Jinan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taixin","family":"Wang","sequence":"additional","affiliation":[{"name":"Qilu Pharmaceutical Co. Ltd.  Jinan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Tan","sequence":"additional","affiliation":[{"name":"Peking University HuiLongGuan Clinical Medical School Beijing HuiLongGuan Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University HuiLongGuan Clinical Medical School Beijing HuiLongGuan Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01121-6"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby058"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0444-6"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01556-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1324-3517"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2007.07.012"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-071984"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115036"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020361"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081063"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4378"},{"key":"e_1_2_9_15_1","unstructured":"Research FCFDEA \u201cClinical Pharmacology Andbiopharmaceutics Review(s) for 022524ORIG1S000 \u201d2024."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-6485"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.954"},{"key":"e_1_2_9_18_1","unstructured":"EMA \u201cGuideline on the Investigation of Bioequivalence \u201d2010 http:\/\/www.ema.europa.eu."},{"key":"e_1_2_9_19_1","unstructured":"NMPA \u201cGuidance Principles for Bioequivalence Studies of Generic Chemical Drugs in Humans Using Pharmacokinetic Parameters as Endpoint Evaluation Indicators (Issued by NMPA) \u201d2016 https:\/\/www.nmpa.gov.cn\/index.html."},{"key":"e_1_2_9_20_1","unstructured":"Administration(NMPA) NMP \u201cGuidance Principles for Bioequivalence Studies of Generic Chemical Drugs in Humans Using Pharmacokinetic Parameters as Endpoint Evaluation Indicators (Issued by NMPA) \u201d2016 https:\/\/www.nmpa.gov.cn\/index.html."},{"key":"e_1_2_9_21_1","unstructured":"MHRA \u201cPublic Assessment Report: Aripiprazole 10\u2009mg Orodispersible Tablets (UK Licence No: PL 24668\/0273\u2013276) \u201d2015 https:\/\/products.mhra.gov.uk."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1783"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003261901"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.5.3.297"},{"key":"e_1_2_9_25_1","unstructured":"FDA \u201cBioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application \u201d2021 https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/bioequivalence\u2010studies\u2010pharmacokinetic\u2010endpoints\u2010drugs\u2010submitted\u2010under\u2010abbreviated\u2010new\u2010drug."},{"key":"e_1_2_9_26_1","unstructured":"ICH \u201cM13A Bioequivalence for Immediate\u2010Release Solid Oral Dosage Forms \u201d2024 https:\/\/www.fda.gov\/."},{"key":"e_1_2_9_27_1","unstructured":"FDA \u201cDraft Guidance on Aripiprazole \u201d2021 http:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1007"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S424694"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S53795"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00779-5"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102011"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0130-3"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjps.galenos.2020.76390"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122753"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120759"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.04.003"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)22379-5"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.80"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091362"},{"issue":"1","key":"e_1_2_9_41_1","first-page":"9","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke C.","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1832990"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:05:00Z","timestamp":1760162700000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/cts.70142"],"URL":"https:\/\/doi.org\/10.1111\/cts.70142","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"2024-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70142"}}